BRAIN CANCER

Latest News

FDA Grants Priority Review for Vorasidenib in IDH-Mutant Diffuse Glioma
FDA Grants Priority Review for Vorasidenib in IDH-Mutant Diffuse Glioma

February 20th 2024

The FDA has accepted and granted priority review for the new drug application for vorasidenib for the treatment of IDH-mutant diffuse glioma, with a PDUFA action date set for August 20, 2024.

Brain Cancer Hope: 19.9 Month Median Survival with New Combo
Brain Cancer Hope: 19.9 Month Median Survival with New Combo

February 6th 2024

TME Pharma Prepares IND Filing for Olaptesed Pegol in GBM Following FDA Meeting
TME Pharma Prepares IND Filing for Olaptesed Pegol in GBM Following FDA Meeting

January 10th 2024

FDA Grants Safe to Proceed Letter to IND of Ropidoxuridine in GBM
FDA Grants Safe to Proceed Letter to IND of Ropidoxuridine in GBM

January 8th 2024

FDA Grants Orphan Drug Designation to DOC1021 for Malignant Glioma
FDA Grants Orphan Drug Designation to DOC1021 for Malignant Glioma

January 3rd 2024

Latest CME Events & Activities

41st Annual Miami Breast Cancer Conference®

March 7, 2024 - March 10, 2024

Register Now!

Optimizing Pain Management for Breast Cancer Surgery Patients in the Age of the Opioid Epidemic

View More

Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?

View More

Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer

View More

Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician

View More

Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

23rd Annual International Congress on the Future of Breast Cancer® East

July 19-20, 2024

Register Now!

Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed

View More

Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease

View More

Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care

View More

Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes

View More

42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Register Now!

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

More News